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ABSTRACT 
Asthma is the leading chronic illness in the pediatric population and affects 
more than 7 million children in the United States. Although effective preventive 
medications are available, medication nonadherence in children and adolescents 
continues to soar. Understanding trends and gaining insight from associations 
between psychometric tests can improve asthma control. The purpose of this 
study is to validate the use of MARS-A (Medication Adherence Report Scale) as 
a tool in assessing asthma medication adherence in a pediatric population as 
well as finding relationships between individual MARS-A items and other asthma 
control measures. One hundred fifty six patients diagnosed with asthma were 
recruited to complete the Asthma Control Test (ACT) and MARS-A questionnaire 
for analysis. 
The results demonstrated that the MARS-A had good internal validity with 
a Cronbach-a of 0.81 for all data, which includes multiple visits per patient. A 
separate analysis of internal validity was performed to factor in sensitivity, using 
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the first and last visit's data only showing once again, good internal consistency 
(Cronbach-a 0.84 for the first visit dates and 0.83 for the last visit dates). 
Furthermore, the MARS-A showed good criterion validity with AMR, ACT, and 
Childhood-ACT (p=0.24 , p=0.0036; p=0.31, p=0.000024; p=0.31 , p=0.00017, 
respectively). Sensitivity analysis across these values demonstrated similar 
results. Patients who reported high adherence according to MARS-A (score of 
46 or higher) had a 3-fold higher odds of scoring higher on the C-ACT (odds ratio 
(OR)= 3.07; 95% confidence interval [CI] = 1.49-6.31 , p = 0.002). If a patient 
scored 0.5 or higher on the AMR, then they are 2.6 times more likely to score 
greater than or equal to 46 on the MARS-A, further supporting good criterion 
validity. 
The MARS-A also sign ificantly correlated with spirometry measures such 
as forced expiratory volume in 1 second (FEV1) (p=0 .17, p=0.004), FEV1/FVC 
(forced vital capacity) ratio (p=0.18, p=0.0031 ), and mid airway flow rate FEF25 
to 75 (p=0.21 , p=0.000521 ). 
Individual MARS-A items M1 ("I only use ICS when I need it"), M2 ("I only 
use it when I feel breathless"), M4 ("I try to avoid using it"), M5 ("I forget to take 
it", M9 ("I use it before doing something which might make breathless"), and M1 0 
("I take it less than instructed") showed significant association with the C-ACT 
score. 
For the individual items in MARS-A and its association with the ACT 
score, only items M2, M5, and M10 showed significant correlation. 
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In relation to spirometry measures, items M1, M3, M?, and M9 correlated 
well with FEV1 (p=0.18, p=O.OO?; p=0.21 , p=0.01; p=0.15, p=0.03; p=0.15, 
p=0.02; p=0.22, p=0.001, respectively). Items M1, M2, MS, M6, and M9 showed 
a significant relationship with the FEV1/FVC ratio (p=0.22, p=O.OOO?; p=0.17 , 
p=0.01; p=0.16, p=0.02; p=0.13, p=0.048; p=0.19, p=O.OOS). 
When MARS-A items were analyzed with Asthma Medication Ratio , M1 
(p=0.20, p=0.02), M2 (p=0.28, p=0.0008), M3 (p=0.16, p=O.OS), MS (p=0.24, 
p=0.003), M1 0 (p=0.22, p=0.009) showed significant correlation at the first visit. 
No significant relationships were established for the AMR during the study. 
Results show that the child answered C-ACT items 1 to 4 correlated 
significantly with the MARS-A scores (parent filled), showing agreement between 
parent and child in maintaining asthma and control. The same relationship was 
established in age group 12 to 18 year olds, although, the patients answered the 
ACT questionnaires themselves. 
Insight from trends within the MARS-A questionnaire can provide pertinent 
information to clinicians to achieve better asthma control. Understanding the 
forms of nonadherence -intentional versus unintentional-the patients tend to 
score lower in can help the physician target and eliminate gaps in knowledge. 
Unintentional nonadherence is when the patient is prevented from implementing 
their intention to take the medication as prescribed by factors that are not 
conscious such as forgetfulness or a poor understanding of the regimen. 
Intentional nonadherence occurs when the patient purposely decides not to take 
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the medication or alters the original agreement between the healthcare provider 
and patient. A patient's health beliefs and illness perceptions are pivotal in 
achieving medication adherence and therefore warrant further investigation to 
obtain optimal adherence. 
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INTRODUCTION 
Asthma is a chronic inflammatory disorder of the airways. Many patients 
with asthma suffer from ongoing symptoms that interrupt daily activities 
compromising quality of life and potentially leading to lower productivity and 
greater health care costs (Masoli et al., 2004 ). The number of people suffering 
from asthma worldwide is 300 million and rising, with an estimate of 400 million 
by 2025, according to the World Health Organization (WHO). In 2006, there were 
approximately 23 million physician-diagnosed cases of asthma in the U.S., and 
about 7 million of those cases were children (1 0% of the childhood population). It 
is the most common chronic illness in children, of which the highest prevalence is 
seen in children ages 5 to 17, constituting 106.3 cases per 1000 persons (Laster 
et al., 2009). In 2011 , approximately 700,000 emergency department (ED) visits, 
200,000 hospital admissions, and almost 200 deaths were caused by asthma in 
those under 15 years of age (WHO, FactSheet, n.d.) (Medical expenses 
associated with asthma reached $50.1 billion in 2007. Such high costs from 
asthma exacerbations and emergency department visits continue to burden this 
country today. Aside from direct health-care costs, indirect costs such as loss of 
parental productivity and missed school days decrease the efficiency of our 
society. From the patient's perspective, having an exacerbation is one of the 
most distressing events for those with childhood asthma. More than half (53%) of 
patients with asthma had an asthma attack in 2008. Of those percentages, 
children had more exacerbations compared to adults (57% vs. 51%). (Center of 
Disease Control and Prevention, CDC, Vital Signs, n.d.) 
Adequate management of persistent asthma can be achieved with 
controller medications such as inhaled corticosteroids (ICSs), which have been 
shown to reduce the risk of exacerbations (O'Bryne et al., 2006). In most cases, 
the pediatric asthmatic patient has a long-term control medication and a quick 
relief medication. The long-term control medications are termed controllers and 
include ICS such as fluticasone proprionate, budesonide, leukotriene modifiers 
such as montelukast; combination inhalers that contain ICS and long-acting beta 
agonists (LABA) such as Advair Diskus and Symbicort. These medications are 
usually taken on a daily basis and serves as the foundation of evidence-based 
management of persistent asthma as indicated on the National Asthma 
Education and Prevention Program (NAEPP) 2007 Expert Panel Report 3 
(Urbano, 2008). The quick-relief medications are short-acting beta agonists 
(SABA) which provide rapid relief during an asthma attack. Examples of such are 
albuterol, levalbuterol , and pirbuterol. Often oral corticosteroids such as 
Prednisone are given to relieve airway inflammation along with SABA. 
Asthma is a complex and multifaceted disease, thus complicating the 
assessment of control and decision to adjust medications among clinicians (Ko et 
al., 2011 ). From a clinical perspective, one of the challenges physicians face is 
determining whether poor asthma control stems from inadequate adherence with 
ICS controller medication or results from intrinsic asthma severity despite 
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adherence to recommended medications. At times, health care providers may 
not ask questions in a manner that encourages honest reporting , thus increasing 
the likelihood of a patient overestimating medication use (Cohen et al. , 2009). 
The National Asthma Education and Prevention Program (NAEPP) and 
Global Initiative for Asthma (GINA) define the goals of asthma control to be 
minimal or no symptoms during the day or night, full physical activity including 
exertion, prevention of exacerbations, maintenance of near normal pulmonary 
function, decreased use of rescue B2-agonist medication, and minimal or no 
adverse effects from medications (Liu et al., 2006). 
Unfortunately, several studies have shown suboptimal adherence to ICS 
revealing typical non-adherent rates around 50% (Bender et al., 2003, Apter et 
al., 2003). For example, studies using low cost methods such as canister 
weighting show that children with asthma only take between 40 to 70 percent of 
prescribed doses, while research using electronic monitoring devices reveal 
children taking only 50 to 60 percent of the prescribed doses (Bender et al., 
2000). 
During the last two decades, asthma experts have shifted their focus from 
managing acute attacks to achieving asthma control (Judd , 2003). The general 
consensus of well controlled asthma includes no daytime symptoms, use of 
bronchodilators or exacerbations, and morning peak expiratory flow 2: 80% in 7 
out of 8 weeks (Meltzer et al., 2010). The Gaining Optimal Asthma Control 
(GOAL) clinical trial revealed <45% of the patients with their asthma under total 
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control even after following intensive therapy. A more recent finding by the 
national telephone survey, CHOICE (Comprehensive Survey of Healthcare 
Professionals and Asthma Patients Offering Insight on Current Treatment Gaps 
and Emerging Device Options) revealed that almost half (490) of the patients 
with asthma participating in the study were not using controller medications. The 
majority of the patients who were not using controllers (79%) had persistent 
asthma and 4 7% had either mild or moderate persistent asthma. Out of 510 
patients on controllers, only 14.4% were categorized as well-controlled (Colice et 
al. , 2012). 
Asthma Control Assessment Tools 
The assessment of asthma control include different biomarkers, 
spirometry measures such as FEV1/FVC (ratio forced expiratory volume in 1 
sec/forced vital capacity) and forced expiratory volume in 1 second (FEV1 ), 
bronchial hyperresponsiveness (BHR), sputum investigations and fractional 
exhaled nitric oxide (FeNO) which show the degree of airway inflammation (Ko et 
al. , 2008). FEV1 is the volume of air that can be blown out in one second after 
expiration. There are some important drawbacks that come with objective 
measures of asthma adherence. Electronic pill bottle monitoring (EPBM) and pill 
counts may give patients the impression that they are not trusted , thus, brewing 
resentment on the patient's end and weakening the patient-doctor relationship 
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(Jerant et al. , 2008). In addition, EPBM caps are expensive and because each 
medication requires its own monitored bottle, participants cannot use adherence-
enhancing pill organizers, potentially leading to recruitment of non-representative 
study samples and falsely decreased adherence estimates. Although using pill 
counts to measure adherence is quick and simplistic, problems with this method 
include the fact that patients can switch medicines between bottles and discard 
pills before their visit with an asthma specialist or primary care physician 
(Osterberg et al., 2005). A similar study by lvanova et al. confirmed that objective 
measures may also lead to surreptitious discarding of medication, leading to 
inflated adherence estimates. Finally, prescription databases provide indirect 
estimates of adherence which may correlate poorly with other methods of 
assessing adherence. Given these drawbacks of objective measures, patient 
self-reported questionnaires provide a more practical approach to aid in 
assessing medication adherence, reflecting the individual perspectives of chronic 
diseases such as asthma (Jerant et al., 2008). 
Furthermore, in the busy clinic setting, it is difficult to perform a full range 
of objective tests such as spirometry, FeNO, and induced sputum in addition to 
taking a detailed history and comprehensive physical examination. Additionally, 
simple self-administered questionnaires can complement pulmonary function 
testing and other assessments by health care providers. As noted in a 
Medication Adherence Report Scale for Asthma (MARS-A) study, many 
physicians rely heavily on self-report for assessing adherence to medications in 
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real-world practice (Cohen et al., 2009). There is also no consensus on a "gold 
standard" of electronic monitoring of adherence since it is both costly and time-
consuming. One other barrier in asthma control is the fact that spirometry cannot 
be performed in children younger than 5 years of age and not generally used in 
the primary care setting (Zhou et al., 2009). Limitations such as equipment and 
time prevent primary care physicians from using spirometry to assess asthma 
control, as recommended in the NHLBI EPR-3 2007 guidelines. In order to 
improve these limitations, simple, yet validated tools such as self-reported 
questionnaires can be an alternative option . 
Asthma Questionnaires 
The Asthma Control Test (ACT) is a 25 point five-item questionnaire that 
tests asthma control in adults and adolescents 12 years and older. An emphasis 
is placed on asthma control 4 weeks prior to the doctor's visit and two cut points 
have been identified and incorporated into the EPR3 asthma guidelines, 19 and 
15. Patients scoring :2: 20 are well controlled, ::; 19 are not well controlled, and ::; 
15 very poorly controlled. It has been shown that the Asthma Control Test (ACT) 
correlates better with treatment decisions made by asthma specialists as 
compared to spirometry, peak expiratory flow rate (PEFR), and FeNO (Ko et al., 
2008), thereby indicating that asthma control cannot be inferred from objective 
measures of airway function alone. 
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Children under 12 years of age have several quality-of-life assessments 
and clinical questionnaires to help determine symptoms; however a simple 
validated tool for asthma control was lacking. Therefore, the 7 item Childhood 
Asthma Control Test (C-ACT) intended for children 4 to 11 years of age was 
adapted from the ACT and validated by Liu and colleagues. The C-ACT was 
designed to include input from parent and child and capture the multidimentional 
aspects of asthma control with a potential range of scores from 0 to 27. It 
contains 4 child-reported questions regarding daytime and exercise-induced 
asthma symptoms, self-report of how they feel about their asthma at the present 
visit, and nighttime awakenings due to asthma on a 4 point scale from 0 to 3. The 
last 3 questions are completed by caregivers on a 6 point scale from 0 to 5. 
Clinical validity results further support of a cut-off point of 19 or less in the C-ACT 
as indicative of inadequate asthma control. In order to mirror the NAEPP 
guidelines and cut off values for the ACT, Liu and colleagues performed 
additional statistical analyses to determine whether a second cut point for the C-
ACT could distinguish children with very poorly controlled asthma from not well 
controlled . They determined that a cut point of 12 has a sensitivity of 32.76% 
(correctly identifying this percentage rated by the specialist as "very poor 
controlled") and a specificity of 89.76% (correctly classified patients as "not well 
controlled"). Their findings are now used in clinics where a score on the C-ACT 
of 20 or greater is well controlled , score of 13 to 19 is not well controlled , and a 
score of 12 or less is very poorly controlled (Liu et al., 201 0). 
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Another frequently used psychometric test is the Medication Adherence 
Report Scale (MARS, Appendix 1) developed by Rob Horne. Further validation 
by Cohen et al. determined the validity of using the MARS for asthmatic patients 
(MARS-A) .. The MARS-A is a 10 item questionnaire rated on a 5 point Likert 
scale with a focus on assessing ICS use. This measure allows physicians in the 
real-word practice to rely on the patient's self-report for assessing adherence 
with therapy. Pharmacy data estimates of adherence, especially in managed 
care settings such as Veterans facilities, often comes with delay as the 
information is known months after the medication is dispensed. The types of 
questions include both generic ("I use it regularly every day") and asthma-specific 
questions about medication use ("I only use it when I feel breathless"). 
Furthermore, it also assesses intentional, such as avoiding use of medications, 
and non-intentional adherence such as forgetting to use the controller 
medication. The questions are written with negative statements to factor in social 
desirability bias and suggesting that non-adherence is normal (Cohen et al., 
2009). 
Other measures of asthma control 
The Asthma Medication Ratio (AMR) is often used as a measure to help 
healthcare providers assess the quality of asthma care received by asthmatic 
patients. Many studies have shown that the AMR to be a better predictor of acute 
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asthma exacerbations than previous measures of controller medication use 
(Schatz et al., 2004; Schatz et al., 2005). The ratio is calculated by the number of 
controller medication to the total asthma medication, including rescue inhalers, 
used by an asthmatic patient. As demonstrated in Schatz' study, a ratio of 0.5 or 
greater has been determined to be adequate asthma control. 
The results of the validation of MARS-A in an adult population by Cohen et 
al. showed that the questionnaire was significantly correlated with better 
electronic adherence as retrieved from pharmacy data. The internal consistency 
measured with the Cronbach-a, or the degree items are related to one another, 
was 0.85 at when the questionnaire was administered at baseline and 1 month, 
and 0.84 at 3 months. The study concluded that the MARS-A fulfills the three 
most desirable features of a survey instrument- good internal validity, good 
criterion validity when compared with electronically measured adherence of ICS 
use, and strong construct validity. Further studies confirmed the significant 
association MARS-A had with electronic monitoring (Ohm et al., 2006. Mahler, 
2010) and pill counting (Menckeberg et al., 2008). A more recent longitudinal 
study showed that nine out of ten items on the questionnaire were suitable for 
assessing intentional non-adherence because the results were invariant over 
time. (Mora et al., 2011 ). These findings suggest that the MARS-A is a reliable 
tool that is capable of tracking non-adherence over a period of time. 
Aside from asthma, the MARS has also been used to assess adherence in 
patients with multiple chronic conditions as well as cardiovascular disease 
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revealing internal consistency (r=0.60-0.69) using the Cronbach-a test. Test-
retest reliability was satisfactory with values of r=0.61 and r=0.63 for the above 
mentioned, respectively (Liu et al., 2006). 
Numerous studies have indicated poor correlations between the symptom 
reports of children and the parents according to a study by Liu et al. (201 0). In an 
effort to understand the reasons behind non-adherence, studies have shown that 
the mean level of adherence in children was approximately half of their 
prescribed preventive medication (McQuaid et al., 2003). Furthermore, older 
children were associated with poorer adherence where adherence to preventive 
medications did not show significant differences by gender, asthma severity or 
family socioeconomic status. 
McQuaid et al. found that there was a significant difference between adherence 
in Caucasian and non-Caucasian participants. The study showed that the 
average score was 7 4 percent correct on the Newcastle Asthma Knowledge 
Questionnaire (AKQ) and that young girls were more knowledgeable about 
asthma than young boys. In addition, knowledge was significantly related to age. 
Older child age was associated with poorer adherence and adherence to 
preventive medications did not differ by gender, asthma severity or by family 
socioeconomic status. Significant differences between adherence of Caucasian 
and non-Caucasian participants were found. The study showed that the average 
knowledge score was 7 4 percent correct on the AKQ and that girls were more 
knowledgeable about asthma than boys, and knowledge was significantly related 
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to age. However, correlational analyses indicated that factual knowledge about 
asthma was not related to medication adherence. The study further suggested 
that medication adherence had a negative correlation with child age. 
Another interesting study attempted to research the relationship between 
the amount of responsibility in managing asthma in children and age. They found 
that there was a strong overall linear increase in child daily controller 
management (DCM) responsibility as they increased with age, and a 
complementing decrease in parent DCM responsibility (Orrell-Valente, 2008). 
The sample represented children ages 4 to 19. 
Additionally, Guyatt et al. 1999 observed that younger ch ildren (age < 11 
years old) and their symptom reports strongly correlated with quality of life 
measures. However, the parents' ratings only showed a weak correlation with 
FEV1 and asthma control, and did not correlate with quality of life measures. This 
study concluded that it is especially important for clinicians to obtain information 
from both children and their parents in assessing asthma control. 
Other asthma adherence related studies focused on perceived racial 
differences as a contributing factor due to differences in socioeconomic status 
and an urban lifestyle (McDaniel et al. , 2012). Social factors that are commonly 
found in urban poverty such as mental illness, single parent status, and financial 
stress is a confounding factor in managing chronic illnesses such as asthma. 
Despite ample research on various aspects of childhood asthma, very little 
is known about the relationship between the individual items on MARS-A and 
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other measures of asthma control in children. With the burden of asthma in 
children and adults increasing a rapid rate, it is important to identify psychological 
and behavioral trends to further enhance and support patients in achieving 
adherence. Advancement in adherence questionnaires can further assist the 
provider in order to better assess asthma control. Investigation of the breakdown 
of commonly lower scoring items on self-reported questionnaires can provide 
valuable behavioral information pertinent to asthma control. 
Specific Aims: 
A significant number of studies have been conducted evaluating varying 
parameters associated with childhood asthma. Many studies investigated the 
reliability of patient self-reported questionnaires in an effort to assess asthma 
control. The parent study from which this data is derived (Wojtczak et al., 20 12) 
examines the correlation between MARS-A and other psychometric tests such as 
the ACT, spirometry, Asthma Medication Ratio (AMR), and the Rescue Index 
(RI). It is important to compare the MARS-A to accepted measures of adherence 
to further While recent studies have examined the use of such questionnaires, 
few have looked at the individual trends and correlation of the items within these 
psychometric tests . 
Thus, in this study, we aim to: 
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(1) Demonstrate the valid ity of MARS-A in a pediatric population as 
compared to the ACT™, C-ACT™, and electronic medication adherence 
assessed by pharmacy refill data (AMR) 
(2) Evaluate specific items on the MARS-A in uncontrolled and controlled 
patients. Primary outcomes for this analysis will be: (a) To determine 
which behavioral patterns/question were most discriminatory in predicting 
asthma control by comparing AMR and spirometry data before and after 
the study 
(3) Analyze the correlation between MARS-A, C-ACT, ACT and actual 
adherence in children of different age groups to determine the usefulness 
of parental questionnaires. Four primary outcomes evaluated will be: (a) 
How well does the MARS-A score and C-ACT score correlate in children 
4-11 years old and 12-18 years old? (b) How well do parent-answered 
questions on the MARS-A and C-ACT relate to child-answered questions 
on the C-ACT. (c) How do the MARS-A and ACT subjective measures 
compare to objective measures such as the Asthma Medication Ratio 
(AMR) and spirometry results? 
We expect these studies to show: 
(1) The MARS-A to be a valid assessment for asthma medication adherence 
in the pediatric population 
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(2) The most common item that is scored lower on the MARS-A and whether 
that item supports unintentional or intentional nonadherence. 
(3) That children aged 4-11 years would have a closer correlation between 
MARS-A and C-ACT, when compared to children 12-18 years. 
(4) Any discrepancy between the patient (4-11 year old) and parent's 
perception of the child 's asthma control 
14 
METHODS 
Sample 
The data presented here is a subset of a multicenter observational study 
in the process of publication under the direction of Dr. Allan Wachter, Chief 
Medical Officer of Foundation for Asthma Research and Intervention (FARI) and 
his colleagues, Dr. Henry Wojtczak and Dr. Joseph Yusin (Wojtczak et al., 2012). 
Although the parent study consisted of patient data from PVAHCS and NMCSD, 
the current study is a preliminary analysis of individual item relationships on the 
MARS-A with other psychometric tests and objective measures at NMCSD only. 
IRB approval was obtained at the Naval Medical Center of San Diego (NMCSD, 
Dr. Wojtczak). Potential subjects were identified by asthma ICD-9 codes. 
Recruitment at the NMCSD pediatric asthma clinic was carried out by the 
principal investigator and clinic nurses. Inclusion criteria included: (1) patients 
diagnosed with persistent asthma based on the NCQA HEDIS administrative 
database criteria. (2) age from 4 years old with no upper age limit (in the NMCSD 
study, age ranges from 4 to 18). Subject exclusion criteria included: (1) diagnosis 
of COPD, (2) patients unable to perform spirometry, complete a questionnaire or 
follow advice of the physician or nurse determined by the principal investigators, 
3) serious comorbidities (cancer, CHF), (4) patients unavailable for clinic follow-
up over the next 12 months, 5) age less than 4 years old. 
Of the 159 patients at NMCSD, 156 patients agreed to participate in this 
study. There were no dropouts from the study. There were no differences in age 
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or ethnicity between those who did and those who did not choose to participate. 
Written informed consent was obtained . The NMCSD patients were enrolled from 
June 2010 to May 2011. 
Questionnaire Administration 
The C-ACT™ was used for children 4 to 11 years of age with 
parents/gauardians answering questions 5 to 7. The ACT™ was administered to 
patients 12 years of age and older. Both ACT™ and C-ACT™ are validated 
reliable questionnaires that assess asthma control over the last 4 weeks of 
baseline health (excluding exacerbations). Scores equal to or less than 19 were 
considered 'out-of-control'. A global score of 20 or more indicates proper asthma 
control. The MARS-A questionnaire is a 1 0-item self-reported measure of 
adherence with ICS, assessing both intentional and non-intentional non-
adherence. Questions were phrased in the negative to set a tone of non-
adherence being normal. Medication use was rated on a 5-point Likert scale. 
MARS-A Questionnaires were filled out by the parents at NMCSD. 
For the analyses, tests were run using all data as well as only first and last 
visits ' values for ACT™ , MARS-A, FEV1 and FEV1 /FVC spirometric 
measurements to account for sensitivity, since some patients had three or more 
visits while others only had one visit. Children aged 4 to 11 years old filled out 
part of the C-ACT as indicated on the instructions and children aged 12 to 18 
years of age filled out the ACT on their own. Both age groups had the MARS-A 
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completed by the parents. All patients performed spirometry (FEV1 and 
FEV1/FVC) at follow-up appointments. A total of 287 visits were recorded. 
NMCSD uses Armed Forces Health Longitudinal Technology Application 
(AHL TA) as part of its EMR and pharmacy claim data system. AHLTA permits 
pharmacy claim extraction from certain civilian pharmacy claims databases. 
Pharmacy claim data was obtained by two methodologies. Pharmacies at 
NMCSD provided batch data on all asthma refill data one year prior to each 
subject from time of enrollment and at a study completion . No program was 
available to calculate AMR. The PI at NMCSD reviewed the batch data and 
compared it with actual refill data in each patient's chart. There were no 
differences in refill claim data when batch data was compared to actual patient 
refill use in AHL TA. 
Pharmacy claim data was obtained as a single time measurement at the 
end of the study. Both controller and short acting B2 agonist (SABA) medications 
dispensed were tracked in NMCSD AHL TA. Controller medications recorded 
included: inhaled corticosteroids (ICS), combination inhaled products of 
corticosteroids/long-acting B2-agonist combination canisters and/or dry-
powdered inhalers (DPis), leukotriene modifiers, and methylxanthines. The 
Asthma Medication Ratio (AMR) is defined by the numerator number of 
controllers dispensed and the denominator of the sum of controllers and SABA 
canisters dispensed using the same time period. Subjects could be excluded if 
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six months of pharmacy claim data was unavailable. No subjects were excluded 
based on this criterion . 
The data collection process was not randomized because the researcher 
approached clients consecutively at each patient visit and asked whether he or 
she wished to participate in the study. The researcher only approached those 
who fit the inclusion criteria. 
Questionnaires with a missing response for one or more statements of 
MARS-A and the ACT or C-ACT were excluded from analysis. For each 
participant, a sum for MARS was calculated ranging from 1 to 50. A score of 1 to 
45 was considered non-adherent and between 46 and 50 adherent. 
Statistical analysis 
Data were analyzed using NCSS (version 7.0, NCSS LLC, Kaysville, UT). 
Correlations were examined both with Pearson's and Spearman Rank 
correlations. The latter was done to address the nonlinearity of the adherence 
measures. The Spearman Rank correlation is better suited for a nonparametric 
sample. 
Validating the MARS-A 
Assessment of the MARS-A as a suitable adherence measure in the 
pediatric population was validated by considering the internal validity, criterion 
validity, and test re-test reliability. The internal validity, the degree to which 
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questions within an instrument agree with each other, of MARS-A was tested by 
determining the Cronbach's alpha coefficient. The criterion validity, a measure of 
whether scores on the questionnaire successfully predict a specific criterion (ex. 
adherence in this case, compared to other validated adherence metrics) was 
completed. A test-retest reliability was performed by linear regression to 
determine if there were variations in measurements taken by the person or 
instrument on the same item under the same conditions. 
The Spearman rank correlation (p) was used to assess the association 
between the disease control metrics (AMR, ACT, and MARS-A) and the 
spirometric determinations FEV1 and FEV1/FVC. Measurements were directly 
taken from the score with no scaling involved. For each correlation performed, 
two different runs were used: all data points available and those of the first and 
last visit only. With the sensitivity factor, first and last visits were analyzed 
together when determining the relationship between MARS-A and other asthma 
control metrics. However, the only difference occurred when looking at the 
relationship between the MARS-A and AMR. The first visit MARS-A score was 
analyzed with the pre study AMR score. The last visit MARS-A score was 
analyzed with the AMR score obtained during the study. The rest of the data was 
not evaluated in this respect. 
To assess the relationship between the individual items on the MARS-A 
and other asthma control metrics (C-ACT, ACT, FEV1 , FEV1/FVC, and AMR), 
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the Spearman correlation was determined. For the individual item analyses, only 
the first and last visit's data was used . 
The Spearman correlation was also used to determine the relationship 
between child-answered items on the C-ACT, parent-answered items on the C-
ACT (Items 5 through 7) and the MARS-A. 
Odds ratio was obtained using the logistic regression function on NCSS to 
determine the likelihood of those scoring ~ 46 on MARS-A to have a score of~ 
0.5 on the AMR as well as~ 20 on the ACT and C-ACT. 
Chi square tests were performed to determine whether two variables were 
independent of each other such as the AMR and MARS-A. 
MARS-A and spirometry measures (FEV1, FEV1/FVC, FEF25 to 75) 
relationships were also determined by the Spearman correlation, utilizing all data 
and that of only the first and last visit. 
MARS-A Individual Item Analysis 
Item analysis of the MARS-A with various asthma control measures were 
demonstrated with the Spearman rank correlation. 
To determine age related patterns in adherence, child answered items on 
the C-ACT in patients age 4 to 11 were correlated with the MARS-A total score. 
ACT and MARS-A were run as noted above. 
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RESULTS 
Patient Characteristics 
The overall cohort included 156 patients with persistent asthma who 
completed the baseline survey (MARS-A). Out of these children, 80 (51%) 
returned for a follow-up. Interviews were conducted in English. 
The majority of the sample was male (64%) and between the ages of 4 to 
11 years old (70%). The mean age of the sample was 9.4 years (Table 1 ). There 
was no significant variation between ethnicities in our patient population. 
Table 1: Patient Demographics 
Variable All patients 4-11 yrs. 12-18 yrs. 
(n = 156) (n = 109) (n = 47) 
Age± SD 9.4 ± 3.7 7.6 ± 2.3 14 ± 1.8 
Female(%) 56 (36) 42 (39) 14 (30) 
Male(%) 100 (64) 67 (61) 33 (70) 
Asthma Control 
Assessing adherence according to the C-ACT is shown in Table 2. The 
mean C-ACT score of patients (4 to 11 years old with a score range of 1-27) was 
21.2 ± 4.27 at the baseline and 21.7 ± 3.99 at the end of the study, showing that 
most of the patient population was under adequate asthma control. 
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The mean ACT score (shown in Table 2 also) was 21.3 ± 4.32 at baseline and 
22.38 ± 2.69 at the last visit, demonstrating most of the patients in the 12 to 18 
year old age group have their asthma adequately controlled. 
Medication Adherence 
Self-reported medication adherence according to MARS-A scores is 
shown in Table 1. The mean (SD) MARS-A score of all patients (range 1-50) was 
43.9 ± 6.84 at the baseline, and 44.8 ± 6.38 at the last visit, showing that patients 
mostly answered rarely or never to each item. The mean (SD) MARS-A score for 
the 4 to 11 year old age group is 44.4 ± 6.54 at baseline and 44.9 ± 6.49 at the 
last visit, and 42.9 ± 7.33 at baseline and 44.2 ± 5.78 at the last visit for the 12 to 
18 year old age group. 
The distribution of data in 4 to 11 year olds is shown below in Figure 1. 
The MARS-A median falls at 48. The 25th percentile value is a 43, thus, showing 
that the values are heavily skewed towards the higher end of the range from 1 to 
50. The C-ACT median is 23 and 19 marks the 25th percentile, therefore 75% of 
patients in this age group scored above a 19. 
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The distribution of data in 12 to 18 year olds is also shown in Figure 1. 
The MARS-A median is 46 and 39 marks the 25th percentile, indicating that 75% 
of patients in this age group scored above a 39. The ACT median is 22.5 and 
20.25 marks the 25th percentile, therefore, 75% of the patients scored above 
20.25 in this age group. 
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Figure 1: MARS-A and C-ACT Scores among 4 to 11 year olds (MARS_A, 
C_ACT_Score) and 12 to 18 year old (MARS_Ax, ACT_Scorex) asthmatic 
patients. 
The MARS-A and C-ACT score distributions for 4 to 11 year olds show high 
adherence (MARS-A<:: 46, C-ACT/ACT <::20) as well as the MARS-A and ACT for 
12 to 18 year olds. Data is highly skewed to the top. The median for MARS-A in 4 
to 11 year olds is 48 and 46 in 12 to 18 year olds. 
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Electronic Adherence 
According to the AMR adherence measure, the mean of all patients was 0.66 ± 
0.25 pre study and 0.83 ± 0.37 during the study (Table 2). The mean for the 4 to 
11 year old age group is 0.63 ± 0.27 in the pre-study, 0.86 ± 0.54 during the 
study; 0.67 ± 0.25 pre-study and 0.79 ± 0.12 during the study for the 12 to 18 
year old group. 
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Table 2: Asthma Adherence Metrics Mean 
Variable All patients 4-11 yrs. 12-18 yrs. (n=156) (n = 109) (n = 47) 
MARS-A1 43.9 ± 6.84 44.4 ± 6.54 42.9 ± 7.33 
MARS-N 44.8 ± 6.38 44.9 ± 6.49 44.2 ± 5.78 
C-ACT1 21.2 ± 4.27 
C-ACF 21 .7 ± 3.99 
ACT1 21 .3 ± 4.32 
22.38 ± 2.69 
ACF 
0.66 ± 0.25 0.63 ± 0.27 0.67 ± 0.25 
AMRpre 
0.83 ± 0.37 0.86 ± 0.54 0.79 ± 0.12 
AMRdur 96.4 ± 14.9 94.7 ± 12.9 
FEV1 1 (%) 96.1 ± 14.8 95.6 ± 11.7 
FEV1 2 (%) 0.87* 0.82* 
FEV1/FVC1 0.86* 0.84* 
93.5 ± 33.6 84.6 ± 23.8 
FEV1/FVC2 
90.8 ± 32.0 85.3 ± 21.9 
FEF25-751•2 
% 
NOTE: Data are presented as mean± SD. 1 =first (baseline) visit, 2 = last visit, pre 
=pre-study, dur =during study, *= small standard deviation 
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Validating MARS-A as an adherence assessment tool 
Internal Validity of MARS-A 
The Cronbach-a for MARS-A was 0.81 for all data, including multiple visits per 
patient. As a means to validate the sensitivity of the adherence measure as well 
as handling the varying number of visits per patient, a Cronbach-a for the 
baseline visit and last visit were calculated to be 0.84 and 0.83, respectively 
(Table 3). 
Criterion Validity of MARS-A 
Table 3 gives the Spearman correlations between self-reported MARS-A scores, 
electronic adherence calculated with the Asthma Medication Ratio (AMR), and 
another validated adherence questionnaire (ACT/C-ACT). Generally, higher 
MARS-A scores was significantly correlated with better electronic adherence as 
measured by AMR among the first patient visits (p=0.24, p=0.0036). This trend 
was not found in the last visits. 
Additional Spearman correlation analyses showed that higher MARS-A 
scores correlated significantly with C-ACT scores (p=0.31 , p=0.000024, 175 data 
points). 
Due to multiple visits per patient and the issue of sensitivity, Spearman 
correlations were performed for the last and first visit, also showing a significant 
correlation between C-ACT and MARS-A (p=0.31, p=0.00017, 140 data points). 
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For the 12 to 18 year old age group, MARS-A also showed a significant 
correlation with the ACT (p=0.42, p=0.00021 , 73 data points). Factoring in 
sensitivity by using first and last visit values showed a similar relationship 
between the two psychometric tests (p=0.40, p=0.0014, 60 data points). 
Alternate analyses comparing patients who scored greater than or equal to a 
score of 46 on MARS-A and greater than or equal a score of 20 on the C-ACT 
showed that patients who reported high adherence according to MARS-A had 3-
fold higher odds of scoring higher on the C-ACT (odds ratio (OR)= 3.07; 95% 
confidence interval [CI] = 1.49-6.31 , p = 0.002). A similar analysis was performed 
between a score of 46 or greater on the MARS-A and greater than or equal to 20 
on the ACT showing an insignificant relationship between the MARS-A and ACT, 
possibly due to limited number of data points (OR = 1.65; 95% Cl = -0.62-4.20, p 
= 0.29). Overall , 57.1% (88/147) of all patients were considered high adherers on 
the first visit accord ing to a MARS-A score of 46 or higher. At the end of the 
study, 60.7% (88/145) of all patients were categorized as high adherers to 
medication . 
Additionally, 78.9% (127/161) of the patients' visits scored a 0.5 or higher 
on the AMR at the beginning of the study and 94.4% at the end of the study 
(152/161 data points). The independence of each variable was tested with a chi 
square test resulting in a p = 0.014 showing that their relationship is significant 
AMR and MARS-A. When patients scored 0.5 or higher on the AMR at the first 
visit , they were 2.6 times more likely to score greater than or equal to 46 on the 
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MARS-A (OR =2.60, 95% Cl = 1.19-5.70, p = 0.017). Spearman correlation tests 
confirmed this relationship between these two variables at the baseline visit with 
a correlation coefficient of 0.24 and p value of 0.004. This relationship was not 
significant between the MARS-A score and the AMR at the last visit (OR= 2.58, 
95% Cl = 0. 7 4-8.95, p = 0.13). Further analysis with the Spearman correlation 
test showed that this relationship was insignificant for the last visits with a p value 
of 0.92 . A Chi square test comparing the relationship between a pre-study AMR 
value~ 0.5 and a MARS-A score~ 46 resulted in a p value of 0.014, suggesting 
that as one metric test increases, the other will as well. No significance was 
found for the AMR obtained during the study that was ~ 0.5 and a MARS-A score 
~ 46 (p = 0.12). 
MARS-A and Spirometry 
Across all patients, Spearman correlations show that the MARS-A is significantly 
correlated with FEV1 (p=0.17, p=0.004 ). Sensitivity analysis using each patient's 
first and last visit's data show this relationship continues to hold (p=0.18, 
p=0.0084). It was also determined that the MARS-A and the FEV1/FVC is 
significantly correlated when analyzed with all data (p=0.18, p=0.0031) as well as 
the first and last visit (p=0.18, p=0.006). Furthermore, a significant relationship 
between the MARS-A and a measure of mid airway flow rate (FEF25 to 75) was 
determined (p=0.21 , p=0.000521 ). Sensitivity analysis confirms this relationship 
(p=0.20, p=0.0026). 
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Table 3: Associations (p) between Self-reported Adherence Scores & Other 
Asthma Control and Adherence Measures 
Variable MARS-A P value MARS-A* P value 
C-ACT 0.31 0.000024 0.31 0.00017 
ACT 0.42 0.00021 0.42 0.0002 
AMRpre 0.24 0.004 
AMRdur -0.007 0.92 
FEV1 0.17 0.004 0.18 0.008 
FEV1/FVC 
0.18 0.0031 0.18 0.006 
0.21 0.0005 0.20 0.003 
FEF25-75 
NOTE: AMR correlations determined by comparing the pre-study value and first 
visit MARS-A, and the during study value with the last visit MARS-A. pre = pre-
study, dur = during study, * = uses data from first and last visits (sensitivity factor) . 
When considering sensitivity, correlation between the filtered first and last visit 
measures were enforced on both ends (MARS-A* correlating with C-ACT, the C-
ACT value was also filtered , despite no asterisk) . 
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MARS-A Item Analysis 
MARS-A Items & C-ACT 
Table 2 shows the correlation coefficient of each item on the MARS-A with 
the C-ACT total score, ACT, AMR, and spirometry measures. The following 
measurements factored in sensitivity and only used data from the first and last 
visit. The results were compared to correlations performed using all data points 
with little variation (data not shown). Utilizing the Spearman correlation test to 
find relationships between MARS-A and C-ACT, the results demonstrate that 
MARS-A Item 1 (M1 , "I only use [insert ICS name] when I need it") significantly 
correlates with the total C-ACT score (M1, p=0.23, p=0.027). Item M2 which 
states "I only use it when I feel breathless" showed weak, but significant 
correlation as well (p=0.27, p=0.01 ). Item M4 stating "I try to avoid using it" had a 
p=0.25 and p value of 0.016. Item M5 stating "I forget to take it" is significantly 
correlates with C-ACT (p=0.20, p=0.059). Item M9 stating "I use it before doing 
something which might make me breathless" also showed weak, but significant 
correlation (p=0.26, p=0.01 ). Finally, Item M1 0 which reads "I take it less than 
instructed" had a correlation coefficient of 0.20 and p value of 0.067. The 
following did not show significant correlation with the total C-ACT score: M3, M6, 
M?, and M8 [(p=0.09, p=0 .39) , (p=0.15, p=0.16), (p=0.17, p=0.11 ), (p=0.09, 
p=0.39), respectively]. 
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For the analysis between MARS-A individual items and the ACT total 
score, only M2, M5 and M 10 significantly correlated between the two variables 
[(p=0.33, p=0.01 ), (p=0.46, p=0.00024), (p=0.35, p=O.OO?), respectively] . Item 
M1 , M3, M4, M6 to M9 had p values> 0.05 (correlation coefficients and p values 
listed in Table 4). 
MARS-A Items & Spirometry Measures 
The following analyses were performed using first and last visit dates' 
data. Spearman correlation tests show that M1 (p=0.18, p=O.OO?), M2 (p=0.21 , 
p=0.001 ), M3 (p=0.15, p=0 .03), M? (p=0.15, p=0.02), and M9 (p=0.22, p=0.001) 
significantly correlate with FEV1 . Other items such as M4, M5, M6, and M8 had p 
values greater than 0.05 (Table 4). 
The correlation between individual MARS-A items and the FEV1/FVC ratio 
was also analyzed. The results showed that a significant correlation occurred 
between the spirometry ratio and M1 (p=0.22, p=O.OOO?), M2 (p=0.17, p=0.01 ), 
M5 (p=0.16, p=0.02), M6 (p=0.13, p=0.048), M9 (p=0.19, p=0.005). Insignificant 
correlation was established with M3, M4, M?, M8, and M10 (Table 4). 
MARS-A Items & AMR 
When determining the relationship of the pre-study AMR and MARS-A at 
the first visit, weak, but significant correlations were found in M1 (p=0.20 , 
p=0 .02), M2 (p=0.28, p=0.0008), M3 (p=0 .16, p=0.05), M5 (p=0.24, p=0.003), 
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M1 0 (p=0.22, p=0.009). No significant findings were discovered with item M6, 
M7, M8, and M9 (Table 4). 
The AMR measured during the study was also correlated with individual 
items on the MARS-A. No significant correlations were found between the two 
variables (data shown in Table 4). 
MARS-A & C-ACT Items answered by parents and children 
Performing a Spearman correlation test revealed that there is a significant 
correlation between the MARS-A total score and child answered C-ACT Items 1 
to 4 (p=0.22, p=0.0032), showing consistency between adherence perceived by 
parents and that of the child . To factor in sensitivity, a similar analysis using first 
and last visit values showing few discrepancy with the correlation coefficient as 
well as the p value using all data (p=0.24, p=0.030). As a means of comparison 
and control, the MARS-A total was evaluated against parent answered C-ACT 
Items 5 to 7, confirming a very significant correlation between the two (p=0.33, 
p=0.000013). Using first and last visit data showed a correlation coefficient of 
0.39 and p value of 0.0002. 
MARS-A and Parent answered C-ACT Questions 5-7 (4-11 y/o, filtered first and 
last): p=0.42, p=0.00021 
As mentioned above, the analysis of the MARS-A total and the ACT 
showed a significantly correlating relationship between the two (p=0.40, 
p=0.0014). 
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Table 4: Correlation between MARS-A Items and other adherence measures 
Variable C-ACT ACT FEV1 FEV1/FVC AMRpre AMRdur 
M1 0.23 0.33 0.18 0.22 0.20 0.001 
(0.027) (0.01) (0.007) (0.0007) (0.02) (0.99) 
M2 0.27 0.33 0.21 0.17 0.28 0.06 
(0.01) (0.01) (0.001) (0.01) (0.0008) (0.52) 
M3 0.09 0.04 0.15 0.098 0.16 -0.11 
(0.39) (0.74) (0.03) (0.14) (0.05) (0.20) 
M4 0.25 0.03 0.07 0.07 0.02 0.02 
(0.016) (0.83) (0.29) (0.29) (0.85) (0.83) 
0.20 0.46 0.09 0.16 0.24 0.02 
M5 (0.05) (0.00024) (0.16) (0.02) (0.003) (0.85) 
0.15 0.17 0.09 0.13 0.01 -0.09 
M6 (0.16) (0.19) (0.19) (0.05) (0.89) (0.32) 
0.17 0.10 0.15 0.11 0.15 0.08 
M7 (0.11) (0.45) (0.02) (0.1 0) (0.07) (0.34) 
0.09 0.19 0.08 0.12 0.11 -0.03 
M8 (0 .39) (0.15) (0.22) (0.07) (0.19) (0.72) 
0.26 0.2 0.22 0.19 0.15 -0.12 
M9 (0.01) (0.12) (0.001) (0.005) (0.08) (0.16) 
0.20 0.35 0.08 0.09 0.22 0.09 
M10 (0.067) (0.007) (0.24) (0.16) (0.009) (0.29) 
NOTE: Data are presented as the Spearman correlation coefficient and p-va lue 
in paranthesis. pre = pre-study, dur = during study 
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DISCUSSION 
This study researched the validity of the MARS-A questionnaire as a tool 
in measuring adherence to ICS in a pediatric asthma population. We further 
investigated the individual items on the MARS-A questionnaire and its 
relationship with other asthma control metrics for trends, an investigation that has 
not been looked at extensively in the literature. Results showed that the MARS-A 
is a valid predictor of asthma adherence in the pediatric population. Additionally, 
some MARS-A individual items were better correlated with asthma control tests 
than others from a bivariate perspective. 
Our results show that MARS-A demonstrated two important features as a 
survey instrument: good internal validity and good criterion validity of the 
questionnaire. These findings are consistent with a previous study that validated 
the tool in an adult population (Cohen et al., 2009). Furthermore, the results from 
this study showed that the MARS-A scores significantly correlated with C-ACT 
scores of pediatric patients aged 4 to 11 and ACT scores of patients 12 to 18 
years old. Even with sensitivity factored into the equation, the association 
between the two metric tests still holds. Patients who score greater than or equal 
to 46 on the MARS-A are three times more likely to score higher on the C-ACT. 
Despite the significant correlation between MARS-A and ACT total scores 
mentioned above, the odds of a MARS-A score of greater than or equal to 46 
and scoring greater than or equal to 20 on the ACT could not be found. This 
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could possibly be due to the limited number of data points available in this age 
group. Overall, the MARS-A appears to be a reliable tool to assess adherence in 
conjunction with the popular ACT and C-ACT surveys. 
Further analysis determined that the MARS-A correlates significantly with 
the AMR, a measure of electronic adherence based on the NMCSD pharmacy 
refill database. The AMR has been shown in a closed healthcare environment to 
be a good predictor for assessing risk for emergency asthma healthcare 
utilization in other studies (Burgess et al., 2011 ; Senthilselvan et al., 2005). 
Results show a trend where patients who scored 0.5 or higher on the AMR at the 
first visit were 2.6 times more likely to score higher than 45 on the MARS-A. This 
association was not found between the MARS-A and the AMR for the last visits . 
A possible reason for this lies in the highly adherent study population, where 
fluctuations or improvements may appear minute. 
A significant association was found between the MARS-A total score and 
spirometry measures such as FEV1, FEV1/FVC Ratio, and mid airway flow rate 
FEF25 to 75. This finding suggests that patients who adhere to their ICS regimen 
tend to perform better on spirometry. However, an issue to be mindful of is the 
fact that spirometry is a measure of lung function at a specific point in time and 
many asthma patients have normal lung function. Therefore, it may not be an 
accurate predictor of asthma exacerbations compared to psychometric tests like 
the ACT. Studies have shown that the ACT is a better predictor of asthma 
exacerbations and control than spirometry (Sorkness & Schatz, 2004 ). 
35 
A deeper investigation of individual items on the MARS-A in our study and 
how they associate with other asthma control metric tests showed interesting 
trends. Items M1, M2, M4, M5, M9, and M1 0 have weak, but significant 
correlation with the C-ACT total score. These results show that when a patient 
answers rarely or never (high score) to Item 1 stating "I only use [insert ICS 
name] when I need it," their C-ACT score tends to fair better. This further 
suggests that these patients have adequate knowledge of differences between 
controller medications versus rescue medications. The controller medications 
should be taken daily, not only according to need based on the NAEPP and 
GINA asthma guidelines. Item 2, which states "I only use it when I feel 
breathless," helps clinicians identify patients who misunderstand the daily usage 
of ICS, which would greatly affect the patient's adherence and assessment of the 
condition of their asthma. Item M4 is an intentional non-adherence measure 
stating "I try to avoid using it." Patients who answer rarely or never will certainly 
be more adherent to their ICS regimen and therefore, expected to score higher 
on the C-ACT. Item M5 measures non-intentional non-adherence, stating "I 
forget to take it," also increases as the C-ACT total increases, as logically 
expected. Patients who forget to take their ICS do not receive the medical 
benefits from the drug, thus, should score lower on asthma control tests . Item 9 
states "I use it before doing something which might make me breathless." 
Patients who score high on this item (rarely= 4, never= 5) have a better 
understanding of the role ICS plays in maintaining and controlling asthma. 
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Patients who uses their controller medications right before strenuous activity are 
more likely to mistaken the ICS as a means for quick relief of asthma symptoms 
than for maintenance. Finally, Item 10 which reads "I take it less than instructed" 
also measures intentional non adherence. Patients who scored low on this value 
will most likely result in decreased asthma control. 
Questions 3, 6, 7, and 8 on the MARS-A did not show evidence for an 
association with C-ACT. Item M3 which reads "I decide to miss a dose" did not 
correlate significantly with the C-ACT total score. The same relationship was 
found for item M6 which reads "I alter the dose." This reflects that our study 
population was adherent in terms of following instructions given by the healthcare 
provider. Furthermore, there was no significant relationship between "I stop 
taking it for a while" and "I use it for a reserve , if my other treatment doesn't work" 
with the C-ACT total score, showing again that patients have a good 
understanding of the meaning of a controller medication as well as following 
medication instructions. 
For the analysis between individual MARS-A items and the ACT, only M2, 
M5, and M10 had correlational significance. It is interesting to note that these 
correlations were also found in the 4 to 11 year old patients who filled out the C-
ACT, thus, suggesting consistency in our findings. There were no significant 
associations between the C-ACT and Items M1 , M3, M4, M6, and M9. 
A weak, but significant correlation was discovered between FEV1 and 
MARS-A Items M1 , M2, M3, M7, and M9. Patients who answered rarely or never 
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to the following: use their ICS when they need it (or maintains daily use of ICS), 
use it when they feel breathless, decide to miss a dose, stop taking it for awhile, 
and use it before doing something which might make the patient breathless, tend 
to have higher FEV1 performance. Patients who answered rarely or never to 
using their ICS when they need it, using it when they feel breathless, forgetting to 
take it, altering the dose, and using it before doing something which might make 
them breathless, tend to have a higher FEV1/FVC Ratio. Across literature, many 
studies have demonstrated that the ACT may be more accurate in assessing 
future exacerbations than spirometry. Since certain MARS-A items correlate well 
with FEV1/FVC ratio, utilizing the MARS-A in clinic regularly may be useful as a 
predictor for both adherence and objective measures taken from spirometry. 
Items M4, M5, M6, and M8 did not show an association with FEV1. Items M3, 
M4, M7, M8, and M10 did not significantly correlate with the FEV1/FVC Ratio. 
There was a significant relationship between the MARS-A Items M 1, M2, 
M3, M5, and M1 0 at the first visit and the pre-study AMR. Patients who scored 
rarely or never (4 or 5) on the following statements: only use their ICS when they 
need it, only use it when they feel breathless, decide to miss a dose, forget to 
take it, and take it less than instructed were more likely to have a higher AMR 
value, thus suggestion better adherence to controller medications. Out of the 5 
significant items on the MARS-A, M3 and M10 measure intentional non-
adherence and M1, M2, M5, and M10 measure unintentional non-adherence. 
This shows that if a patient in our study population were to score lower on the 
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adherence metric MARS-A, it would be mostly likely due to a lack of 
understanding of their disease or education on controller medications. 
Interestingly, the MARS-A individual items did not correlate with the AMR 
calculated during the study. A reasonable explanation for this is due to the highly 
adherent population leaving little room for fluctuations in scores to occur. 
Due to the recent study by Orrell-Valente et al. on age and child daily 
controller-medication responsibility in pediatric patients, we elected to analyze 
the relationship between the child-answered questions on the C-ACT and how 
well it correlates with the parent answered MARS-A score. A significant 
correlation resulted between the child answered C-ACT Items 1 to 4 and the total 
MARS-A score, showing consistency between the parent and child 's perception 
of the child's asthma control. This further suggests that there is a solid and 
communicative relationship between the parent and children aged 4 to 11 years 
old regarding the child's asthma. As a means of control, the MARS-A total was 
evaluated against parent answered C-ACT items 5 to 7, suggesting that the 
parent's answers are reliable and consistent with each other. 
Contrary to our expectations, we found that the parent answered MARS-A 
also correlated well with the patient answered ACT. Several studies have shown 
that adolescents with asthma have a greater risk of disease complications such 
as denial of disease severity, non-adherence to medications and trigger 
avoidance, and other behaviors such as smoking tobacco or marijuana that may 
worsen their asthma (Sadof et al., 2011 ). In our study, the parent answered items 
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matched those answered by patients 12 to 18 years of age, again, suggesting 
positive communication between the parent and child in maintaining asthma 
control. An issue to be aware of is the possibility that the child who is managing 
their asthma medications indicate to their parents that they are adhering , when in 
fact , they are not. Such cases are unlikely in our study population due to the 
highly adherent nature of the patients, who are provided with exceptional care 
and patient education. Therefore, we can infer that there is solid communication 
between parent and child. 
There are strengths and limitations to our study of the MARS-A As with 
any survey, responder bias and inaccurate recall must be considered, because 
all information was self-reported . However, the large sample size and the 
consistency of results with the parent study by Wojtczak, Wachter, and Yusin as 
well as with other metric tests reassures us about the validity of the respondents' 
answers. 
Another limitation is the fact that this was a retrospective study, and 
therefore, further information could not be obtained from patients. We were 
unable to validate the MARS-A in terms of construct validity, the extent of what 
was measured actually being measured. In most cases, this type of validation 
would be performed by interviewing patients and having them answer a few 
questions about their adherence to medications. This study could not show test 
retest reliability, a measure of how reliable the metric is able to demonstrate 
adherence, as shown in Cohen's validation of the MARS-A in an adult 
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population. The reason is due to the retrospective nature of this study and 
lengths in time between visits from our patients (3 to 6 months) as compared to 
baseline, one month , and 3 month measures of the MARS-A Cohen et al. 's 
study. Furthermore, the patients in the study population were highly adherent, 
due to fact that this was based in a specialty clinic with ample resources from a 
pediatric pulmonologist, well-versed nurse, and two respiratory therapists. The 
high degree of adherence is shown in the box and whisker plot above as well as 
in Table 1 where means of various asthma control instruments were calculated. 
With this in mind, this study population may not have been a 
representative population for the majority of childhood asthma patients. Further 
investigation for the trends between individual items on the MARS-A and other 
measures of adherence should be conducted utilizing a large, diverse pediatric 
population , such as a primary care setting , to provide further insight into 
behavioral patterns pertinent to asthma control. Other studies that warrant 
investigation are the associations mentioned above in large, diverse adult 
asthmatic patient populations. 
The findings from this study are congruous with that of the parent study. 
Wojtczak et al. demonstrated the significant correlation between MARS-A and 
FEV1 as well as ACT. The current study confirmed these associations and 
validated the MARS-A as a legitimate tool to assess asthma adherence in a 
pediatric population. Another novel aspect of this study was exploration of the 
trends among individual items in the MARS-A and other metric tests. 
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Investigating the health beliefs of patients may be an important tool in achieving 
adherence in asthmatic patients. Finding associations that can provide useful 
information to clinicians such as items on the MARS-A that have a greater 
tendency to fluctuate in scoring, can better target the problem and enhance 
asthma control. 
Utilization of other behavioral and beliefs of disease questionnaires such 
as the BMQ and AQLQ which address these queries in future prospective 
studies, will provide clinicians important information to improve adherence among 
asthma patients. From these studies will stem targeted interventions to address 
the gap of knowledge and health beliefs that contribute to lower asthma 
adherence. These findings will benefit the patients who are diagnosed with 
asthma as well as patients afflicted with chronic disease that require demanding 
maintenance. 
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APPENDIX 
MEDICATION ADHERENCE REPORT SCALE- ASTHMA (MARS-A) 
Developed by Rob Horne; adjusted by Dr. Henry Wojtczak 
How often do you do the following? 
Answers: (1) Always (2) Often (3) Sometimes (4) Rarely (5) Never 
1 I only use my when I need it. 
2 I only use it when I feel breathless. 
3 I decide to miss a dose. 
4 I try to avoid using it. 
5 I forget to take it. 
6 I alter the dose. 
7 I stop taking it for awhile. 
8 I use it for a reserve, if my other treatment 
doesn't work. 
9 I use it before doing something which might 
make me breathless. 
10 I take it less than instructed. 
TOTAL SCORE 
Copyright of MARS-A and all variants is owned by the originator Robert Horne, 
PhD, and permission to use it should be obtained by requests to 
Rob.horne@pharmacy.ac.uk. 
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Enter Name 
Enler Add!ess 
Enter Ci!yiState/Zlp 
FOR PATIENTS: 
Take the Asthma Control TestTM (ACT) for people 12 yrs and older. 
Know your score. Share your results with your doctor. 
Step 1 Write the number of each answer in the score box provided. 
Step 2 Add the score boxes for your total. 
Step 3 Take the test to the doctor to talk about your score. 
3. ~ lhe past4 weolcs, tow aten cid yox asthma ~ (wheeMg, ~. stmness a bfeath, dleslli!jmess 
« paio) W<J;.e )00 1-P at ni!tt Ot e;rier than usual in the I11CI1irQ? 
4ormort _ IT'\ 
··- v 
5. Ha.ot Vo'!:Ud )00 ..... )'CLI'aslluna oonni cUiiG the past. weeks? 
:.- 0) =-
.,_.,.,.., __ 
.wnt~Tt!llil:t~d~~ 
D 
D 
D 
D 
'Dill 
D 
If your score is 19 or less, your asthma may not be controlled as well as it could be. Talk to 
your doctor. 
FOR PHYSICIANS: 
The ACT is: 
• A simple, 5-question tool that is self-administered by the patient • Recognized by the National Institutes of HeaHh 
• Clinically validated by specialist assessment and spirometly1 
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[ 
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Enl'!fName 
Enter CityiSiate!Z•p 
Talay'sl:lm - - ---
Palierts Narm 
Childhood Asthma Control Test for children 4 to 11 years. 
This testwil JXDVile a saxe thai may~ 1he-detEnTine l you- c!Wl's asdYna tmalmert pi;vl is wal<ing IX fl nVt be line fur a o'lange. 
How to take the Childhood Asthma Control Test 
Step 1 Lei your child respond lo 1he first four questions (11o 4~ If your child needs help reading or understanding the question, you may 
help, bullet your child selecllhe response. Complete the remanlng liYee questions (5 to '7) on your own and without letting your 
chicl's response i-.:e your,._,. There are no right <r """"9 arlSWeiS. 
Step 2 Write the number of each answer n !he score box provided. 
Step 3 Add up each score box for the 10011. 
Step 4 Take the test Ia the dodllr toll!ik about your chid's loti sccre. 
Have your child complete these questions. 
1. -~)'!XI' ........ blay? 
I I 
0 0 
2.fWnu:ll 
l Oo)QiaJ.9lbecal.oed )'W'aslma? 
I 
I 
I ..,. 
0 • Yeo,oldllelirne. Yoo.moololllelirne. 
4. Do )QI-~ dlli1g the tigllbecal.oeoi)'Oll' as1hma? 
I 
I 
I ..,. . 
0 • Y!!Jolollletilw. Y115,moolollletint. 
• • Y!!t-ollletint. 
G 
• Y!!Jsomeollletint. 
Please complete the following questions on your own. 
~· 12!!!!!11!!\l!ilild~ t!IZ!!!!!iml!msli2~!i!!i!!!i!::se~2i!x!i!!!lasttm!S'Indoons? 
• • 0 • • Not alai l1-18days 1!1-24days 
0 
1!1-24days 
OOcause of asllwna? 
• • Notaial 1-3days 4-10days 11-16days 19-24days 
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If you- chid's saxe is 19 IX less. ij 
may be a sign that your child's 
ma is not oontrolled as weH 
as ~ coold be. Bring this test to 
the doctor to talk about the results. 
• Jo  !!!l ..... d ... llma. 
• Jo • No, 110110 ol lletint. 
• )D ~
• D ~
• D ~
'llliOL 
D 
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